Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Apr 12

PMID 33842335

Citations 36

Authors

Shuwen Dong

Zheng Wang

Kunwei Shen

Xiaosong Chen

Affiliations

Soon will be listed here.

Abstract

Metabolic syndrome is a type of multifactorial metabolic disease with the presence of at least three factors: obesity, diabetes mellitus, low high-density lipoprotein, hypertriglyceridemia, and hypertension. Recent studies have shown that metabolic syndrome and its related components exert a significant impact on the initiation, progression, treatment response, and prognosis of breast cancer. Metabolic abnormalities not only increase the disease risk and aggravate tumor progression but also lead to unfavorable treatment responses and more treatment side effects. Moreover, biochemical reactions caused by the imbalance of these metabolic components affect both the host general state and organ-specific tumor microenvironment, resulting in increased rates of recurrence and mortality. Therefore, this review discusses the recent advances in the association of metabolic syndrome and breast cancer, providing potential novel therapeutic targets and intervention strategies to improve breast cancer outcome.

Citing Articles

Unraveling molecular interconnections and identifying potential therapeutic targets of significance in obesity-cancer link.

Abdulla A, Sadida H, Jerobin J, Elfaki I, Mir R, Mirza S J Natl Cancer Cent. 2025; 5(1):8-27.

PMID: 40040878 PMC: 11873641. DOI: 10.1016/j.jncc.2024.11.001.

Correlation between gut microbiota dysbiosis, metabolic syndrome and breast cancer.

Abdelqader E, Mahmoud W, Gebreel H, Kamel M, Abu-Elghait M Sci Rep. 2025; 15(1):6652.

PMID: 39994329 PMC: 11850770. DOI: 10.1038/s41598-025-89801-8.

The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study.

Gu H, Zhu T, Ding J, Yang Z, Lu Y, Guo G Front Oncol. 2025; 15:1402300.

PMID: 39980560 PMC: 11839753. DOI: 10.3389/fonc.2025.1402300.

Complex Role of Circulating Triglycerides in Breast Cancer Onset and Survival: Insights From Two-Sample Mendelian Randomization Study.

Zhang W, Li Z, Huang Y, Zhao J, Guo S, Wang Q Cancer Med. 2025; 14(4):e70698.

PMID: 39960141 PMC: 11831496. DOI: 10.1002/cam4.70698.

Metabolic syndrome is associated with breast cancer mortality: A systematic review and meta-analysis.

Harborg S, Larsen H, Elsgaard S, Borgquist S J Intern Med. 2025; 297(3):262-275.

PMID: 39775978 PMC: 11846077. DOI: 10.1111/joim.20052.

References

Muniz J, Kidwell K, Henry N . Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay. Breast Cancer Res Treat. 2016; 157(3):597-603. PMC: 5095927. DOI: 10.1007/s10549-016-3846-4. View

Fan Y, Ding X, Wang J, Ma F, Yuan P, Li Q . Decreased serum HDL at initial diagnosis correlates with worse outcomes for triple-negative breast cancer but not non-TNBCs. Int J Biol Markers. 2015; 30(2):e200-7. DOI: 10.5301/jbm.5000143. View

Patel D, Srinivasan S, Xu J, Chen W, Berenson G . Adiponectin and its correlates of cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism. 2006; 55(11):1551-7. DOI: 10.1016/j.metabol.2006.06.028. View

Bell L, Nguyen A, Li L, Desta Z, Henry N, Hayes D . Comparison of changes in the lipid profile of postmenopausal women with early stage breast cancer treated with exemestane or letrozole. J Clin Pharmacol. 2011; 52(12):1852-60. PMC: 3616612. DOI: 10.1177/0091270011424153. View

Morgan B, Chai S, Albiston A . GLUT4 associated proteins as therapeutic targets for diabetes. Recent Pat Endocr Metab Immune Drug Discov. 2011; 5(1):25-32. DOI: 10.2174/187221411794351914. View

Ng E, Gao F, Ji C, Ho G, Soo K . Risk factors for breast carcinoma in Singaporean Chinese women: the role of central obesity. Cancer. 1997; 80(4):725-31. DOI: 10.1002/(sici)1097-0142(19970815)80:4<725::aid-cncr11>3.0.co;2-v. View

Perez E, Rodeheffer R . Clinical cardiac tolerability of trastuzumab. J Clin Oncol. 2004; 22(2):322-9. DOI: 10.1200/JCO.2004.01.120. View

Vedin L, Lewandowski S, Parini P, Gustafsson J, Steffensen K . The oxysterol receptor LXR inhibits proliferation of human breast cancer cells. Carcinogenesis. 2009; 30(4):575-9. DOI: 10.1093/carcin/bgp029. View

Lim U, Ernst T, Buchthal S, Latch M, Albright C, Wilkens L . Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. Nutr Diabetes. 2013; 1:e6. PMC: 3302135. DOI: 10.1038/nutd.2011.2. View

10.

Boyd N, McGuire V, Fishell E, Kuriov V, Lockwood G, Tritchler D . Plasma lipids in premenopausal women with mammographic dysplasia. Br J Cancer. 1989; 59(5):766-71. PMC: 2247212. DOI: 10.1038/bjc.1989.160. View

11.

Giles E, Jindal S, Wellberg E, Schedin T, Anderson S, Thor A . Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. Breast Cancer Res. 2018; 20(1):50. PMC: 6000949. DOI: 10.1186/s13058-018-0974-2. View

12.

Litton J, Gonzalez-Angulo A, Warneke C, Buzdar A, Kau S, Bondy M . Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol. 2008; 26(25):4072-7. PMC: 6557586. DOI: 10.1200/JCO.2007.14.4527. View

13.

Sane D, Anton L, Brosnihan K . Angiogenic growth factors and hypertension. Angiogenesis. 2004; 7(3):193-201. DOI: 10.1007/s10456-004-2699-3. View

14.

Lee A, Jo S, Lee C, Shin H, Kim T, Ahn K . Diabetes as a prognostic factor in HER-2 positive breast cancer patients treated with targeted therapy. Breast Cancer. 2019; 26(5):672-680. DOI: 10.1007/s12282-019-00967-2. View

15.

Mirabelli M, Chiefari E, Arcidiacono B, Corigliano D, Brunetti F, Maggisano V . Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. Nutrients. 2020; 12(4). PMC: 7230471. DOI: 10.3390/nu12041066. View

16.

Pfeiler G, Stoger H, Dubsky P, Mlineritsch B, Singer C, Balic M . Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: an analysis of 1509 patients of the ABCSG-06 trial. Br J Cancer. 2013; 108(7):1408-14. PMC: 3629426. DOI: 10.1038/bjc.2013.114. View

17.

Agresti R, Meneghini E, Baili P, Minicozzi P, Turco A, Cavallo I . Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study. Breast Cancer Res Treat. 2016; 157(1):179-89. DOI: 10.1007/s10549-016-3802-3. View

18.

Deliot N, Constantin B . Plasma membrane calcium channels in cancer: Alterations and consequences for cell proliferation and migration. Biochim Biophys Acta. 2015; 1848(10 Pt B):2512-22. DOI: 10.1016/j.bbamem.2015.06.009. View

19.

Protani M, Coory M, Martin J . Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010; 123(3):627-35. DOI: 10.1007/s10549-010-0990-0. View

20.

Baserga R . The contradictions of the insulin-like growth factor 1 receptor. Oncogene. 2000; 19(49):5574-81. DOI: 10.1038/sj.onc.1203854. View